Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Brendan Frett
Univ of Arkansas for Med Scis, Department: None
Should you be removed from our database? Contact us at [email protected]. Read more below.
Synactix Pharmaceuticals, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The Investigator has an equity interest in Synactix Pharmaceuticals, Inc. which has licensed Intellectual Property the Investigator holds from the University of Arizona. He serves as Key Personnel on research that has the potential to impact the value of the company and the intellectual property.
Selective RET Kinase and Its Mutant Inhibitors for the Treatment of Medullary Thyroid Cancer
Cancer is the second leading cause of death in United States, and new therapeutics are desperately needed to combat this disease. Due to the challenges of identifying a selective RET inhibitor, an effective treatment of medullary thyroid cancer (MTC) is still an unmet medical need. In a new research effort we will utilize validated computational models of RET and fragment-based screening to develop a RET inhibitor clinical candidate with a high kinase selectivity profile. The resulting selective RET inhibitor is expected to increase MTC survival from months to multiple years.
Filed on October 05, 2018.
Tell us what you know about Brendan Frett's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Brendan Frett”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Brendan Frett | Univ of Arkansas for Med Scis | Conflict of Interest | Synactix Pharmaceuticals, Inc. | Value cannot be readily determined |
| Brendan Frett | Univ of Arkansas for Med Scis | Conflict of Interest | Synactix Pharmaceuticals, Inc. | Value cannot be readily determined |
| Brendan Frett | Univ of Arkansas for Med Scis | Conflict of Interest | Synactix Pharmaceuticals, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.